Other authors focused on transferring T cell co-stimulatory receptor (OX40/CD137) mRNA to tumor-infiltrating T cells by phospholipid-based nanoparticles (PLNPs) as these receptors are often downregulated in these immune cells, limiting the use of antibodies as an immunotherapeutic strategy. This evidence concerns the gene TNFRSF4 and neoplasm.